Solo disponible en BuenasTareas
  • Páginas : 20 (4915 palabras )
  • Descarga(s) : 0
  • Publicado : 21 de enero de 2011
Leer documento completo
Vista previa del texto
Antianemic agent containing iron and difructose
United States Patent 5700832

According to the present invention, an antianemic agent for the treatment of anemia caused by iron-deficiency containing iron and difructose. Iron and difructose contained in the said antianemic agent may form a complex, and their appropriate molar ratio is within the scope of 1:0.5 to 1:1000.
Further, theantianemic agent in accordance with the present invention may additionally contain hematopoietics such as cyanocobalamine, pyridoxine hydrochloride, folic acid, etc.
Baik, Bu Hyun (Seoul, KR)
Lee, Young Woo (Seoul, KR)
Lee, Yong Bok (Kwangju, KR)

What is claimed is:

1. An antianemic agent for the treatment of anemia caused by iron-deficiency, wherein the agent enhances iron absorptionacross the intestinal lumen to mucosal cell while promoting iron transport across the mucosal cell to capillary, and the agent consists of an iron and difructose complex having an iron to difructose molar ratio of between 1:0.5 to 1:1000, and optionally at least one hematopoietic. 

2. An antianemic agent according to claim 1, wherein the molar ratio of iron to difructose is within the scope of1:0.5 to 1:10. 

3. An antianemic agent according to claim 1, which consists of said iron and difructose complex having an iron to difructose molar ratio of between 1:0.5 to 1:1000. 

4. An antianemic agent according to claim 1, wherein the at least one hematopoietic is selected from the group consisting of cyanocobalamine, pyridoxine hydrochloride and folic acid. 

The present invention relates to an antianemic agent effective in the treatment of iron deficiency anemias and more particularly, to an antianemic agent containing iron and difructose as it is or in the form of complex, thus increasing the iron absorption and decreasing the gastrointestinal disorders.
Anemia is a condition in which the concentration of the oxygen-carryinghemoglobin or red blood cells is below normal. The most common form of anemia is iron-deficiency anemia, comprising about 25% of all anemia-related patients. The causes of iron-deficiency anemia are diseases, diet that does not provide enough iron, or poor absorption of iron from diet. Another causes are extra needs in old people, children or pregnant women. Irrespective of the underlying causes, thecomplete treatment caused by iron-deficiency anemia relies on the administration of iron supplements but a prolonged therapy should be maintained until iron is stored in the body.
However, iron has a relatively low absorption rate of only about 5 to 15%. When absorbed and ionized in the body, iron preparations produces gastro-intestinal irritation, therefore upper abdominal pain, vomiting,diarrhea, etc. These irritant side-effects occur in 15 to 20% of orally administered patients but in these cases, the reduced drug compliance of patients may sometimes lead to the failure in the treatment of anemias. In this respect, to minimize these side-effects associated with iron preparations, it is recommended to reduce the contents of iron in the treatment of anemias, but this remainsinsufficient owing to a low absorption of iron.
The main site of iron absorption is duodenum and absorption is influenced by the following factors : 1) internal factors in the body, 2) iron concentration in the gastrointestinal lumen, 3) chemical form of iron administered, 4) pH of the gastrointestinal lumen, and 5) iron solubility in the gastrointestinal lumen.
To be free from the aforementioned defectsrelated to a low absorption of iron and side-effects incurred out of the intake of iron preparations, many studies have been incessantly made to increase the iron solubility using some pharmaceutical additives such as ascorbic acid, citric acid, fructose, sorbitol, maltol, etc. M. E. Conrad and S. G. Schade, Gastroenterology, 55(1), 35-45(1968), J. M. Hopping and W. S. Ruliffson, Am. J....